Brendan D. Curti
Expertise in
14
conditions

Dr. Brendan D. Curti

Oncology
4805 Northeast Glisan Street, Suite 11N-1, 
Portland, OR 
Offers Telehealth
Expertise in
14
conditions
4805 Northeast Glisan Street, Suite 11N-1, 
Portland, OR 

Overview

Brendan Curti is an Oncologist in Portland, Oregon. Dr. Curti is highly rated in 14 conditions, according to our data. His top areas of expertise are Melanoma, Renal Cell Carcinoma (RCC), Prostate Cancer, and Chromophobe Renal Cell Carcinoma.

His clinical research consists of co-authoring 78 peer reviewed articles and participating in 29 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in OR

Hospital Affiliations

Ohsu Hospital And Clinics
Providence Portland Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Moda Health
  • EPO
  • PPO
Prominence Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

4805 Northeast Glisan Street, Suite 11N-1, Portland, OR 97213

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

29 Clinical Trials

A Phase I/II Study of MK-3475 With Gemcitabine in Patients With Previously-Treated Advanced Non-small Cell Lung Cancer (NSCLC)
A Phase I/II Study of MK-3475 With Gemcitabine in Patients With Previously-Treated Advanced Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drugs: MK-3475, Gemcitabine
Study Phase: Phase 1/Phase 2
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Biological
Study Drugs: RP1, Nivolumab
Study Phase: Phase 2
A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma
A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma
Enrollment Status: Completed
Publish Date: December 09, 2025
Intervention Type: Biological
Study Drug: Lifileucel
Study Phase: Phase 2
A Phase Ib Study to Assess the Safety, Tolerability and Immunologic Activity of Preoperative IRX 2 In Early Stage Breast Cancer
A Phase Ib Study to Assess the Safety, Tolerability and Immunologic Activity of Preoperative IRX 2 In Early Stage Breast Cancer
Enrollment Status: Completed
Publish Date: December 03, 2025
Intervention Type: Drug, Dietary supplement
Study Drugs: Cyclophosphamide, Indomethacin, Omeprazole
Study Phase: Phase 1
A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Cancers
A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Cancers
Enrollment Status: Completed
Publish Date: August 20, 2025
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Biological, Drug
Study Drugs: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
Study Phase: Phase 2
Intratumoral Ipilimumab in Head and Neck Cancer
Intratumoral Ipilimumab in Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drug: Ipilimumab
Study Phase: Phase 1
A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Chemotherapy in Metastatic Triple Negative Breast Cancer Patients
A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Chemotherapy in Metastatic Triple Negative Breast Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Paclitaxel, Capecitabine
Study Phase: Phase 1/Phase 2
A Phase II Study of Nivolumab Combined With Bicalutamide and Ipilimumab in Metastatic HER2-negative Breast Cancer
A Phase II Study of Nivolumab Combined With Bicalutamide and Ipilimumab in Metastatic HER2-negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab, Bicalutamide
Study Phase: Phase 2
Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Renal Cancer
Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Renal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Radiation, Biological
Study Drug: High Dose IL-2
Study Phase: Phase 2
A First-in-Human Phase 1 Study of NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
A First-in-Human Phase 1 Study of NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
Enrollment Status: Completed
Publish Date: October 01, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Multicentre Phase 2b Trial to Evaluate the Efficacy and Tolerability of ModraDoc006/r in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC), Suitable for Treatment With a Taxane
A Multicentre Phase 2b Trial to Evaluate the Efficacy and Tolerability of ModraDoc006/r in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC), Suitable for Treatment With a Taxane
Enrollment Status: Completed
Publish Date: April 17, 2024
Intervention Type: Drug
Study Drugs: Docetaxel, ModraDoc006/r
Study Phase: Phase 2
Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI6469) Administered Prior to Definitive Surgical Resection Patients With Locoregionally Advanced, Oral Head and Neck Squamous Cell Carcinoma
Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI6469) Administered Prior to Definitive Surgical Resection Patients With Locoregionally Advanced, Oral Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: February 07, 2024
Intervention Type: Drug, Procedure
Study Drug: MEDI6469 Anti-OX40 Antibody
Study Phase: Phase 1
Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients With Metastatic Melanoma, Non-Small Cell Lung Cancer, and Head and Neck Squamous Cell Carcinoma.
Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients With Metastatic Melanoma, Non-Small Cell Lung Cancer, and Head and Neck Squamous Cell Carcinoma.
Enrollment Status: Completed
Publish Date: June 05, 2023
Intervention Type: Drug
Study Drugs: Galactoarabino-Rhamnogalactouronate, Pembrolizumab
Study Phase: Phase 1
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: May 01, 2023
Intervention Type: Drug
Study Drugs: SEA-CD40, Pembrolizumab, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 1
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
Enrollment Status: Completed
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: IMCgp100
Study Phase: Phase 1/Phase 2
A PHASE 1b STUDY OF INTRATUMORAL CAVATAK® (COXSACKIEVIRUS A21, CVA21) AND IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA (VLA-013 MITCI)
A PHASE 1b STUDY OF INTRATUMORAL CAVATAK® (COXSACKIEVIRUS A21, CVA21) AND IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA (VLA-013 MITCI)
Enrollment Status: Completed
Publish Date: January 17, 2023
Intervention Type: Biological, Drug
Study Phase: Phase 1
Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252
Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252
Enrollment Status: Active_not_recruiting
Publish Date: December 09, 2022
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Phase I/Ib Study of Surgical Resection or Radiofrequency Ablation (RFA) of Metastatic Lesions in the Liver in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Metastatic Colorectal Cancer
Phase I/Ib Study of Surgical Resection or Radiofrequency Ablation (RFA) of Metastatic Lesions in the Liver in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drug: MEDI6469
Study Phase: Phase 1
A Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors
A Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 2 Study to Assess the Safety and Efficacy of Scalp Cooling Using PenguinTM Cold Caps for the Prevention or Reduction of Chemotherapy-induced Alopecia in Stage I-III Breast Cancer
A Phase 2 Study to Assess the Safety and Efficacy of Scalp Cooling Using PenguinTM Cold Caps for the Prevention or Reduction of Chemotherapy-induced Alopecia in Stage I-III Breast Cancer
Enrollment Status: Unknown
Publish Date: September 16, 2020
Intervention Type: Device
Study Phase: Not Applicable
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Enrollment Status: Completed
Publish Date: June 13, 2019
Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy.
Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy.
Enrollment Status: Completed
Publish Date: March 21, 2019
Intervention Type: Biological
Study Phase: Phase 1
Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma
Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma
Enrollment Status: Completed
Publish Date: March 21, 2019
Intervention Type: Biological
Study Phase: Phase 1
A Study to Determine the Immunopheotype of Locally Advanced Rectal Adenocarcinoma and Its Correlation With the Efficacy of Neoadjuvant Chemoradiotherapy
A Study to Determine the Immunopheotype of Locally Advanced Rectal Adenocarcinoma and Its Correlation With the Efficacy of Neoadjuvant Chemoradiotherapy
Enrollment Status: Completed
Publish Date: August 29, 2018
Intervention Type: Genetic, Procedure
Phase I Study of Safety and Immunogenicity of ADU-623, a Live-attenuated Listeria Monocytogenes Strain (ΔactA/ΔinlB) Expressing the EGFRvIII-NY-ESO-1 Vaccine, in Patients With Treated and Recurrent WHO Grade III/IV Astrocytomas
Phase I Study of Safety and Immunogenicity of ADU-623, a Live-attenuated Listeria Monocytogenes Strain (ΔactA/ΔinlB) Expressing the EGFRvIII-NY-ESO-1 Vaccine, in Patients With Treated and Recurrent WHO Grade III/IV Astrocytomas
Enrollment Status: Completed
Publish Date: August 17, 2018
Intervention Type: Biological, Drug
Study Phase: Phase 1
Phase I Study of Alpha-tocopheryloxyacetic Acid (α-TEA) in Patients With Advanced Cancer
Phase I Study of Alpha-tocopheryloxyacetic Acid (α-TEA) in Patients With Advanced Cancer
Enrollment Status: Completed
Publish Date: August 17, 2018
Intervention Type: Drug
Study Phase: Phase 1
Randomized Phase II Trial of Cyclophosphamide With Allogeneic Non-Small Cell Lung Cancer (NSCLC) DRibble Vaccine Alone or With Granulocyte-Macrophage Colony-Stimulating Factor or Imiquimod for Adjuvant Treatment of Definitively-Treated Stage IIIA or IIIB NSCLC
Randomized Phase II Trial of Cyclophosphamide With Allogeneic Non-Small Cell Lung Cancer (NSCLC) DRibble Vaccine Alone or With Granulocyte-Macrophage Colony-Stimulating Factor or Imiquimod for Adjuvant Treatment of Definitively-Treated Stage IIIA or IIIB NSCLC
Enrollment Status: Completed
Publish Date: July 06, 2017
Intervention Type: Drug, Biological
Study Phase: Phase 2
View 28 Less Clinical Trials

78 Total Publications

Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial.
Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial.
Journal: Nature communications
Published: April 25, 2025
Similar Doctors
Expertise in
8
conditions
Dr. Brian Druker
Oncology
Expertise in
8
conditions
Dr. Brian Druker
Oncology

OHSU Hospital

3181 SW Sam Jackson Park Rd, 
Portland, OR 
 (6.4 miles away)
503-494-5596
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Brian Druker is an Oncologist in Portland, Oregon. Dr. Druker is highly rated in 8 conditions, according to our data. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Leukemia, Acute Myeloid Leukemia (AML), and Philadelphia-Negative Chronic Myeloid Leukemia.

Expertise in
12
conditions
Dr. Rachel E. Sanborn
Oncology
Expertise in
12
conditions
Dr. Rachel E. Sanborn
Oncology
4805 Northeast Glisan Street, Suite 11N-1, 
Portland, OR 
 (2.4 miles away)
503-215-5696
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rachel Sanborn is an Oncologist in Portland, Oregon. Dr. Sanborn is highly rated in 12 conditions, according to our data. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Bone Marrow Aspiration. Dr. Sanborn is currently accepting new patients.

Expertise in
10
conditions
Dr. Shivaani Kummar
Oncology
Expertise in
10
conditions
Dr. Shivaani Kummar
Oncology

OHSU Hospital

3181 SW Sam Jackson Park Rd, 
Portland, OR 
 (6.4 miles away)
503-314-7168
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shivaani Kummar is an Oncologist in Portland, Oregon. Dr. Kummar is highly rated in 10 conditions, according to our data. Her top areas of expertise are Desmoid Tumor, Alveolar Soft Part Sarcoma, Ovarian Cancer, and Melanoma.

Frequently Asked Questions about Dr. Brendan D. Curti

How do I make an appointment with Dr. Brendan D. Curti?

You can book an appointment with Dr. Brendan D. Curti by calling their office at 503-215-5696. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Brendan D. Curti a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Brendan D. Curti is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Brendan D. Curti specialize in?

While Dr. Brendan D. Curti is a Oncology, they have specific expertise in Melanoma, Renal Cell Carcinoma (RCC), and Prostate Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Brendan D. Curti participate in research or clinical trials?

Yes. Dr. Brendan D. Curti has published 78 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Brendan D. Curti's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Brendan D. Curti accept my insurance?

Dr. Brendan D. Curti accepts most major insurance plans, including Aetna and Cigna. We recommend calling the office directly at 503-215-5696 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Curti's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile